Preventative topical diclofenac treatment differentially decreases tumor burden in male and female Skh-1 mice in a model of UVB-induced cutaneous squamous cell carcinoma

Carcinogenesis

Volumn 34, Issue 2, 2013, Pages 370-377

  Burns, Erin M ^a   Tober, Kathleen L ^a   Riggenbach, Judith A ^a   Schick, Jonathan S ^a   Lamping, Keith N ^a   Kusewitt, Donna F ^b   Young, Gregory S ^a   Oberyszyn, Tatiana M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION INDUCED NEOPLASM; SEX DIFFERENCE; SKIN CARCINOMA; SKIN DEFECT; TOPICAL TREATMENT; TUMOR VOLUME; ULTRAVIOLET B RADIATION;

ADMINISTRATION, TOPICAL; ANIMALS; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; FEMALE; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, HAIRLESS; NEOPLASM GRADING; NEOPLASMS, RADIATION-INDUCED; SKIN NEOPLASMS; TUMOR BURDEN; ULTRAVIOLET RAYS;

EID: 84873542029     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs349     Document Type: Article

References (60)

1. Howlader, N. et al. (2009) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, 2012. Last accessed 24 June 2012.
2. Armstrong,B.K. et al. (2001) The epidemiology of UV induced skin cancer. J. Photochem. Photobiol. B, Biol., 63, 8-18.
3. Rogers,H.W. et al. (2010) Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch. Dermatol., 146, 283-287.
4. The Lewin Group. (2005) The Burden of Skin Diseases 2005. SID and The American Academy of Dermatology Association, Schaumburg, IL.
5. Housman,T.S. et al. (2003) Nonmelanoma skin cancer: an episode of care management approach. Dermatol. Surg., 29, 700-711.
6. Boukamp,P. (2005) Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis, 26, 1657-1667.
7. Setlow,R.B. et al. (1993) Wavelengths effective in induction of malignant melanoma. Proc. Natl. Acad. Sci. U.S.A., 90, 6666-6670.
8. de Gruijl,F.R. (1999) Skin cancer and solar UV radiation. Eur. J. Cancer, 35, 2003-2009.
9. de Gruijl,F.R. (2000) Photocarcinogenesis: UVA vs UVB. Meth. Enzymol., 319, 359-366.
10. Hall,H.I. et al. (1997) Sun protection behaviors of the U.S. white population. Prev. Med., 26, 401-407.
11. McCarthy,E.M. et al. (1999) Beach holiday sunburn: the sunscreen paradox and gender differences. Cutis., 64, 37-42.
12. Gawkrodger,D.J. (2004) Occupational skin cancers. Occup. Med. (Lond)., 54, 458-463.
13. Thomas-Ahner,J.M. et al. (2007) Gender differences in UVB-induced skin carcinogenesis, inflammation, and DNA damage. Cancer Res., 67, 3468-3474.
14. Elmets,C.A. et al. (1982) Ultraviolet radiation effects on immune processes. Photochem. Photobiol., 36, 715-719.
15. Kripke,M.L. (1991) Immunological effects of ultraviolet radiation. J. Dermatol., 18, 429-433.
16. Rivas,J.M. et al. (1994) The role of IL-4, IL-10, and TNF-alpha in the immune suppression induced by ultraviolet radiation. J. Leukoc. Biol., 56, 769-775.
17. Gallagher,R.P. et al. (1995) Sunlight exposure, pigmentation factors, and risk of nonmelanocytic skin cancer. II. Squamous cell carcinoma. Arch. Dermatol., 131, 164-169.
18. Marks,R. (1988) Role of childhood in the development of skin cancer. Aust. Paediatr. J., 24, 337-338.
19. Strickland,P.T. et al. (1989) Quantitative carcinogenesis in man: solar ultraviolet B dose dependence of skin cancer in Maryland watermen. J. Natl. Cancer Inst., 81, 1910-1913.
20. Wilgus,T.A. et al. (2000) Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. Prostaglandins Other Lipid Mediat., 62, 367-384.
21. Fischer,S.M. et al. (1999) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet lightinduced skin carcinogenesis. Mol. Carcinog., 25, 231-240.
22. Buckman,S.Y. et al. (1998) COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis, 19, 723-729.
23. Herschman,H.R. (1996) Prostaglandin synthase 2. Biochim. Biophys. Acta, 1299, 125-140.
24. Hla,T. et al. (1992) Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U.S.A., 89, 7384-7388.
25. Ristimäki,A. et al. (1994) Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J. Biol. Chem., 269, 11769-11775.
26. Wu,K.K. (1996) Cyclooxygenase 2 induction: molecular mechanism and pathophysiologic roles. J. Lab. Clin. Med., 128, 242-245.
27. Hall,P.A. et al. (1993) High levels of p53 protein in UV-irradiated normal human skin. Oncogene, 8, 203-207.
28. Brash,D.E. et al. (1991) A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. U.S.A., 88, 10124-10128.
29. Ziegler,A. et al. (1994) Sunburn and p53 in the onset of skin cancer. Nature, 372, 773-776.
30. Pence,B.C. et al. (1990) Effects of single-dose ultraviolet radiation on skin superoxide dismutase, catalase, and xanthine oxidase in hairless mice. J. Invest. Dermatol., 95, 213-216.
31. Shindo,Y. et al. (1994) Dose-response effects of acute ultraviolet irradiation on antioxidants and molecular markers of oxidation in murine epidermis and dermis. J. Invest. Dermatol., 102, 470-475.
32. Gupta,A. et al. (2001) Attenuation of catalase activity in the malignant phenotype plays a functional role in an in vitro model for tumor progression. Cancer Lett., 173, 115-125.
33. Sander,C.S. et al. (2002) Photoaging is associated with protein oxidation in human skin in vivo. J. Invest. Dermatol., 118, 618-625.
34. Sander,C.S. et al. (2003) Oxidative stress in malignant melanoma and nonmelanoma skin cancer. Br. J. Dermatol., 148, 913-922.
35. Kwei,K.A. et al. (2004) Transcriptional repression of catalase in mouse skin tumor progression. Neoplasia, 6, 440-448.
36. Liu,J. et al. (2009) Protandim, a fundamentally new antioxidant approach in chemoprevention using mouse two-stage skin carcinogenesis as a model. PLoS ONE, 4, e5284.
37. Sullivan,N.J. et al. (2012) UV light B-mediated inhibition of skin catalase activity promotes Gr-1+ CD11b+ myeloid cell expansion. J. Invest. Dermatol., 132(3 Pt 1), 695-702.
38. Wilgus,T.A. et al. (2003) Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol. Carcinog., 38, 49-58.
39. Mazières,B. (2005) Topical ketoprofen patch. Drugs R. D., 6, 337-344.
40. Rivers,J.K. et al. (1997) An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch. Dermatol., 133, 1239-1242.
41. Nelson,C. et al. (2004) Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J. Drugs Dermatol., 3, 401-407.
42. Johannesdottir,S.A. et al. (2012) Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer, 118, 4768-4776.
43. Dunnett,C. (1955) A multiple comparison procedure for comparing several treatments with a control. J. Am. Statist. Assoc., 50, 1096-1121.
44. Hsu,J. (1992) The factor analytic approach to simultaneous inference in the general linear model. J. Comput. Graph. Stat., 1, 151-168.
45. Sinha,P. et al. (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res., 67, 4507-4513.
46. Ostrand-Rosenberg,S. et al. (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol., 182, 4499-4506.
47. Anderson,L. et al. (2009) Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J. Am. Acad. Dermatol., 60, 934-943.
48. Siller,G. et al. (2009) PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas. J. Dermatol., 50, 16-22.
49. Siller,G. et al. (2010) PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas. J. Dermatol., 51, 99-105.
50. Cozzi,S.J. et al. (2012) Ingenol mebutate field-directed treatment of UVBdamaged skin reduces lesion formation and removes mutant p53 patches. J. Invest. Dermatol., 132, 1263-1271.
51. Zhang,Y. et al. (2011) PGE2 promotes angiogenesis through EP4 and PKA Cγ pathway. Blood, 118, 5355-5364.
52. Buchanan,F.G. et al. (2003) Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J. Biol. Chem., 278, 35451-35457.
53. Sheng,H. et al. (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res., 58, 362-366.
54. Sheng,H. et al. (2001) Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem., 276, 18075-18081.
55. Pai,R. et al. (2002) Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med., 8, 289-293.
56. Newell,B. et al. (2003) Comparison of the microvasculature of basal cell carcinoma and actinic keratosis using intravital microscopy and immunohistochemistry. Br. J. Dermatol., 149, 105-110.
57. Nijsten,T. et al. (2004) Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br. J. Dermatol., 151, 837-845.
58. Florence,M.E. et al. (2011) Angiogenesis in the progression of cutaneous squamous cell carcinoma: an immunohistochemical study of endothelial markers. Clinics (Sao. Paulo)., 66, 465-468.
59. Jeter,J.M. et al. (2012) Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study. Cancer Causes Control, 23, 1451-1461.
60. Heyneman,C.A. et al. (2000) Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs, 60, 555-574.